drugset / Trial / NCT00238628
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
Phase 1/2
Completed
6 enrolled
Stanford University
AstraZeneca · collabLigand Pharmaceuticals · collab
Open-label
Summary
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
Timeline
- Start
- 2004-04
- Primary completion
- 2005-04
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexarotene | Small molecule | — | — |
| Subject | Gefitinib | Small molecule | — | — |